Different customer segments have fundamentally different pain points. The value proposition must be segment-specific, not generic.
Pain: Patent cliffs accelerating, need innovation pipelines not just generics. Struggling to compete on novel drug discovery.
Our value: AI-powered drug repurposing, biomarker-driven formulation science, NCE discovery at 1/5th the cost of US CROs. Regulatory dossiers India-ready.
Pain: Need to diversify discovery into APAC populations. India data is siloed, unstructured, underutilized.
Our value: Access to India's unique genomic diversity. Pre-validated cohorts. Faster IND-enabling data packages. Cost-effective Phase 0 studies.
Pain: Can't afford full computational biology + wet lab teams. Discovery infrastructure is the bottleneck, not ideas.
Our value: Discovery-as-a-Service. Pay-per-program. Full-stack from hypothesis to validated lead without building a lab.
Pain: Rich clinical data, no AI-multiomics capability to convert it to insights or IP.
Our value: Clinical data → multiomics → biomarker discovery pipeline. Co-IP arrangements. Revenue share on licensing.
Pain: Grant-funded research needs commercial translation. IP generation without commercialization pathways.
Our value: Translational research platform. Co-IP. BIRAC/DBT grant co-application partner. De-risked innovation.
Pain: Singapore (A*STAR/Biopolis) needs APAC platform plays. Japanese pharma (Takeda, Astellas) seeking Asia discovery partners.
Our value: Pan-APAC discovery network, diverse population datasets, Singapore as regulatory bridge to FDA/EMA.